‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s
Nutrition experts are raising concerns about the potential for malnutrition and muscle loss among patients using GLP-1 weight-loss drugs like Ozempic and Wegovy. Research from the University of Newcastle highlights a critical lack of data regarding the long-term health risks of rapid weight loss associated with these medications.
Why it matters
As GLP-1 usage surges, identifying and mitigating nutritional deficiencies is essential to prevent serious health complications like heart problems and brain damage.
Save You have reached your maximum number of saved items.
Remove items from your saved list to add more.
Gift Gift icon 0 / 3 No gift articles left
You've used all of your gift articles. 3 more will become available on the 1st of every month.
Share A A A Some of the millions of Australians expected to use Ozempic and other GLP-1s could run the risk of malnutrition and muscle loss, but the extent of these complications is not being tracked, nutrition experts warn.
There is a critical gap in evidence focused on the health hazards of rapid weight loss and GLP-1s (glucagon-like peptide-1 receptor agonists), new research from the University of Newcastle found. Extreme cases of malnutrition carry the risk of brain damage, heart problems and death.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in